The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges

Metabolism. 2016 Sep;65(9):1342-9. doi: 10.1016/j.metabol.2016.06.001. Epub 2016 Jun 12.

Authors

Pingping Yang¹, Tianlun Huang², Gaosi Xu³

Affiliations

¹ Medical Center of the Graduate School, Nanchang University, China; Department of Nephrology, the Second Affiliated Hospital of Nanchang University, China.
² Department of Nephrology, the Second Affiliated Hospital of Nanchang University, China.
³ Department of Nephrology, the Second Affiliated Hospital of Nanchang University, China. Electronic address: gaosixu@163.com.

PMID: 27506741
DOI: 10.1016/j.metabol.2016.06.001

No abstract available

Keywords: Diabetic kidney disease; Endothelin; Finerenone; Mineralocorticoid receptor antagonists.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Aldosterone / metabolism
Diabetic Nephropathies / drug therapy*
Drug Therapy, Combination / methods
Drug Therapy, Combination / trends
Humans
Mineralocorticoid Receptor Antagonists / therapeutic use*
Naphthyridines / therapeutic use

Substances

Mineralocorticoid Receptor Antagonists
Naphthyridines
finerenone
Aldosterone